drugset / Trial / NCT05657639
CAV Regimen for R/R AML
Phase 2
Recruiting
68 enrolled
The First Affiliated Hospital of Soochow University
Affiliated Hospital of Nantong University · collabFirst Affiliated Hospital of Zhejiang University · collabJining Medical University · collabKaifeng Central Hospital · collabNorthern Jiangsu People's Hospital · collabSuzhou Hospital of Traditional Chinese Medicine · collabThe First Affiliated Hospital of Anhui Medical University · collabThe First Affiliated Hospital of Bengbu Medical University · collabThe First People's Hospital of Changzhou · collabThe Second People's Hospital of Huai'an · collabYANCHENG NO.1 PEOPLE'S HOSPITAL · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to investigate the efficacy and safety of cladribine, combined with low-dose cytarabine and venetoclax (CAV regimen) for relapsed/refractory acute myeloid leukemia (R/R AML).
Timeline
- Start
- 2022-10-01
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cladribine | Small molecule | 5 mg/m2 | — |
| Subject | Cytarabine | Small molecule | 20 mg | — |
| Subject | Cytarabine | Small molecule | 1000 mg/m2 | — |
| Subject | Etoposide | Small molecule | 100 mg/m2 | — |
| Subject | Mitoxantrone | Small molecule | 8 mg/m2 | — |
| Subject | Venetoclax | Small molecule | 400 mg | — |